209 related articles for article (PubMed ID: 37452013)
1. Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity.
Rodriguez M; Trevisan B; Ramamurthy RM; George SK; Diaz J; Alexander J; Meares D; Schwahn DJ; Quilici DR; Figueroa J; Gautreaux M; Farland A; Atala A; Doering CB; Spencer HT; Porada CD; Almeida-Porada G
Nat Commun; 2023 Jul; 14(1):4206. PubMed ID: 37452013
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
3. In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment.
Kao YT; Yen CC; Fan HC; Chen JK; Chen MS; Lan YW; Yang SH; Chen CM
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003601
[TBL] [Abstract][Full Text] [Related]
4. Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels.
Trevisan B; Rodriguez M; Medder H; Lankford S; Combs R; Owen J; Atala A; Porada CD; Almeida-Porada G
Front Immunol; 2022; 13():1070476. PubMed ID: 36532079
[TBL] [Abstract][Full Text] [Related]
5. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
6. In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A.
Kumar P; Gao K; Wang C; Pivetti C; Lankford L; Farmer D; Wang A
Cell Transplant; 2018 Jan; 27(1):130-139. PubMed ID: 29562772
[TBL] [Abstract][Full Text] [Related]
7. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
8. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
10. In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A.
Hemşinlioğlu C; Aslan ES; Taştan C; Çakırsoy D; Turan RD; Seyis U; Elek M; Sır Karakuş G; Günaydın ÖS; Abanuz S; Kançağı DD; Yurtsever B; Yalçın K; Kasap M; Ovalı E
Turk J Haematol; 2023 May; 40(2):118-124. PubMed ID: 37022209
[TBL] [Abstract][Full Text] [Related]
11. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
12. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
13. FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.
Lövgren KM; Larsen MS; Zintner SM; Small JC; Kjelgaard-Hansen M; Häger M; Petersen M; Wiinberg B; Margaritis P
J Thromb Haemost; 2020 Jul; 18(7):1586-1597. PubMed ID: 32196903
[TBL] [Abstract][Full Text] [Related]
14. Coagulation factors with improved properties for hemophilia gene therapy.
Pipe SW
Semin Thromb Hemost; 2004 Apr; 30(2):227-37. PubMed ID: 15118934
[TBL] [Abstract][Full Text] [Related]
15. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A.
Porada CD; Sanada C; Long CR; Wood JA; Desai J; Frederick N; Millsap L; Bormann C; Menges SL; Hanna C; Flores-Foxworth G; Shin T; Westhusin ME; Liu W; Glimp H; Zanjani ED; Lozier JN; Pliska V; Stranzinger G; Joerg H; Kraemer DC; Almeida-Porada G
J Thromb Haemost; 2010 Feb; 8(2):276-85. PubMed ID: 19943872
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetics of hemophilia A].
De Brasi CD; Slavutsky IR; Larripa IB
Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
[TBL] [Abstract][Full Text] [Related]
18. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
19. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
[TBL] [Abstract][Full Text] [Related]
20. Hemophilia A--from basic science to clinical practice.
Klinge J; Ananyeva NM; Hauser CA; Saenko EL
Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
